|
1.
|
Tsai HM. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med. 2013 Mar; 126(3):200-9.
|
|
|
|
|
2.
|
Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost. 2012 Jul; 38(5):469-82.
|
|
|
|
|
3.
|
Tsai HM. von Willebrand factor, shear stress, and ADAMTS13 in hemostasis and thrombosis. ASAIO J. 2012 Mar-Apr; 58(2):163-9.
|
|
|
|
|
4.
|
Tsai HM. Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time? Kidney Int. 2010 Feb; 77(4):267-9.
|
|
|
|
|
5.
|
Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010 Jan; 91(1):1-19.
|
|
|
|
|
6.
|
Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl. 2009 Feb; (112):S11-4.
|
|
|
|
|
7.
|
Zhou W, Tsai HM. N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood. 2009 Jan 22; 113(4):929-35.
|
|
|
|
|
8.
|
Dong L, Chandrasekaran V, Zhou W, Tsai HM. Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura. Am J Hematol. 2008 Oct; 83(10):815-7.
|
|
|
|
|
9.
|
Tsai HM. The kidney in thrombotic thrombocytopenic purpura. Minerva Med. 2007 Dec; 98(6):731-47.
|
|
|
|
|
10.
|
Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am. 2007 Aug; 21(4):609-32, v.
|
|
|
|
|
11.
|
Zhou W, Bouhassira EE, Tsai HM. An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers. Blood. 2007 Aug 1; 110(3):886-93.
|
|
|
|
|
12.
|
Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billström R, Björk P, Holmberg L, Karpman D. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr. 2007 Mar; 166(3):249-57.
|
|
|
|
|
13.
|
Tsai HM. ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther. 2006 Nov; 4(6):813-25.
|
|
|
|
|
14.
|
Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006 Jul; 70(1):16-23.
|
|
|
|
|
15.
|
Hirata S, Okamoto H, Ohta S, Kobashigawa T, Uesato M, Kawaguchi Y, Tateishi M, Hara M, Kamatani N, Tsai HM. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease. Rheumatology (Oxford). 2006 Aug; 45(8):1046-7.
|
|
|
|
|
16.
|
Tsai HM, Raoufi M, Zhou W, Guinto E, Grafos N, Ranzurmal S, Greenfield RS, Rand JH. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2006 May; 95(5):886-92.
|
|
|
|
|
17.
|
Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med. 2006; 57:419-36.
|
|
|
|
|
18.
|
Zhou W, Dong L, Ginsburg D, Bouhassira EE, Tsai HM. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? J Biol Chem. 2005 Dec 2; 280(48):39934-41.
|
|
|
|
|
19.
|
Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005 Oct; 115(10):2752-61.
|
|
|
|
|
20.
|
Zhou W, Inada M, Lee TP, Benten D, Lyubsky S, Bouhassira EE, Gupta S, Tsai HM. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005 Jun; 85(6):780-8.
|
|
|
|
|
21.
|
Tsai HM. Molecular mechanisms in thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2004 Oct; 30(5):549-57.
|
|
|
|
|
22.
|
Tsai HM. A journey from sickle cell anemia to ADAMTS13. J Thromb Haemost. 2004 Sep; 2(9):1510-4.
|
|
|
|
|
23.
|
Schiff DE, Roberts WD, Willert J, Tsai HM. Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency. J Pediatr Hematol Oncol. 2004 Aug; 26(8):535-8.
|
|
|
|
|
24.
|
Zhou W, Tsai HM. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost. 2004 Apr; 91(4):806-11.
|
|
|
|
|
25.
|
Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004 Mar; 124(6):787-95.
|
|
|
|
|
26.
|
Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apher. 2004; 19(2):86-9.
|
|
|
|
|
27.
|
Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost. 2003 Oct; 29(5):479-88.
|
|
|
|
|
28.
|
Tsai HM. Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. J Thromb Haemost. 2003 Sep; 1(9):2038-40; discussion 2040-5.
|
|
|
|
|
29.
|
Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost. 2003 Apr; 1(4):625-31.
|
|
|
|
|
30.
|
Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol. 2003 Apr; 14(4):1072-81.
|
|
|
|
|
31.
|
Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003 Mar; 70(3):183-5.
|
|
|
|
|
32.
|
Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood. 2003 Jun 1; 101(11):4449-51.
|
|
|
|
|
33.
|
Tsai HM. Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2003 Mar 1; 23(3):388-96.
|
|
|
|
|
34.
|
Forman RB, Benkel SA, Novik Y, Tsai HM. Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy. Acta Haematol. 2003; 109(3):150-2.
|
|
|
|
|
35.
|
Jubinsky PT, Moraille R, Tsai HM. Thrombotic thrombocytopenic purpura in a newborn. J Perinatol. 2003 Jan; 23(1):85-7.
|
|
|
|
|
36.
|
Tarr PI, Tsai HM, Chandler WL. Thrombotic microangiopathies. N Engl J Med. 2002 Dec 26; 347(26):2171-3; author reply 2171-3.
|
|
|
|
|
37.
|
Tsai HM. Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Blood. 2002 Nov 15; 100(10):3839-40; author reply 3840-2.
|
|
|
|
|
38.
|
Tsai HM. Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Transfusion. 2002 Nov; 42(11):1523-4; author reply 1524-5.
|
|
|
|
|
39.
|
Tsai HM, Sarode R, Downes KA. Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood. Thromb Res. 2002 Nov 1; 108(2-3):121-5.
|
|
|
|
|
40.
|
Pham PT, Danovitch GM, Wilkinson AH, Gritsch HA, Pham PC, Eric TM, Kendrick E, Charles LR, Tsai HM. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation. 2002 Oct 27; 74(8):1077-80.
|
|
|
|
|
41.
|
Tsai HM. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med (Berl). 2002 Oct; 80(10):639-47.
|
|
|
|
|
42.
|
Tsai HM. Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura. Int J Hematol. 2002 Aug; 76 Suppl 2:132-8.
|
|
|
|
|
43.
|
Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002 May-Jun; 28(3):385-91.
|
|
|
|
|
44.
|
Tsai HM, Tarr PI. Rebuttal to: von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost. 2002 Mar; 87(3):548-9; author's reply 549-50.
|
|
|
|
|
45.
|
Robson WL, Tsai HM. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy. Pediatrics. 2002 Feb; 109(2):322-5.
|
|
|
|
|
46.
|
Morgensztern D, Kharfan-Dabaja MA, Tsai HM, Lian EC. Warm-antibody autoimmune hemolytic anemia developing after thrombotic thrombocytopenic purpura. Acta Haematol. 2002; 108(3):154-6.
|
|
|
|
|
47.
|
Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001 Oct 4; 413(6855):488-94.
|
|
|
|
|
48.
|
Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res. 2001 May; 49(5):653-9.
|
|
|
|
|
49.
|
O'Brien JR, Tsai HM, Etherington MD. A comparison of von Willebrand Factor antigen with platelet activity in vitro in normal and venous occlusion blood. Platelets. 2001 Feb; 12(1):27-33.
|
|
|
|
|
50.
|
Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab. 2001; 47(7-8):387-92.
|
|
|
|
|
51.
|
Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J. 2001; 2(5):292-9.
|
|
|
|
|
52.
|
Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol. 2000 Nov; 65(3):251-5.
|
|
|
|
|
53.
|
O'Brien JR, Tsai HM, Etherington MD. Defective von willebrand factor activity detected by the filterometer in three clinical conditions. Platelets. 2000 Nov; 11(7):388-94.
|
|
|
|
|
54.
|
Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000 Jun 15; 342(24):1773-7.
|
|
|
|
|
55.
|
Sarode R, Goldstein J, Sussman II, Nagel RL, Tsai HM. Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor. Br J Haematol. 2000 Jun; 109(4):857-64.
|
|
|
|
|
56.
|
Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000 May 16; 132(10):794-9.
|
|
|
|
|
57.
|
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998 Nov 26; 339(22):1585-94.
|
|
|
|
|
58.
|
Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJ, Bracke M, Furlan M, Tsai HM, de Groot PG, Sixma JJ, Vink T. von Willebrand factor without the A2 domain is resistant to proteolysis. Thromb Haemost. 1997 May; 77(5):1008-13.
|
|
|
|
|
59.
|
Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood. 1997 Mar 15; 89(6):1954-62.
|
|
|
|
|
60.
|
Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996 May 15; 87(10):4235-44.
|
|
|
|
|
61.
|
Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994 Apr 15; 83(8):2171-9.
|
|
|
|
|
62.
|
Kaul DK, Nagel RL, Chen D, Tsai HM. Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood. 1993 May 1; 81(9):2429-38.
|
|
|
|
|
63.
|
Tsai HM, Nagel RL, Hatcher VB, Sussman II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood. 1989 Jun; 73(8):2074-6.
|
|
|
|